Compare Neurocrine Biosciences Inc (NBIX) vs United Airlines Holdings Inc (UAL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs United Airlines Holdings Inc — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while United Airlines Holdings Inc trades at $107.4 (market cap $35.13B). The key difference: United Airlines Holdings Inc is far larger — about 2.2× Neurocrine Biosciences Inc's market cap. Which is the better fit depends on your goals.
| NBIX | UAL | |
|---|---|---|
Market Cap | $15.77B | $35.13B |
Sector | Health | Industrials |
52-Week High | $185.50 | $136.11 |
52-Week Low | $123.10 | $85.21 |
Enterprise Value | $15.78B | $52.16B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
United Airlines (UAL) trades at $108.24, down 2.82% today, with a bearish technical signal but strong fundamentals including a P/E of 10.13 and net income margin of 5.56%. Recent earnings beats and a major international expansion announced in August 2026 highlight growth potential, though cash flow turned negative in 2025 due to capital investments.
The outlook is positive with a consensus price target of $168.96 (56% upside), supported by 66% analyst buy ratings. Risks include high jet fuel costs and geopolitical tensions, but robust travel demand and efficient operations position UAL for recovery if macroeconomic pressures ease.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About United Airlines Holdings Inc
United Airlines is a major U.S. network carrier. United's hubs include San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international travel than legacy peers.
Read more on UAL →
